Jan D. Andersson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jan D. Andersson has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
A.J.B. McEwan
University of Alberta, Medical Isotope and Cyclotron Facility, Department of Oncology, Edmonton, AB, Canada
2 shared publications- Bryce J. B. Nelson
Department of Oncology, University of Alberta, 11560 University Ave., Edmonton, AB T6G 1Z2, Canada
2 shared publications - Frank Wuest
Department of Oncology, University of Alberta, Cross Cancer Institute, 11560 University Avenue, Edmonton, AB, T6G 2X4, Canada.
2 shared publications J.S. Wilson
University of Alberta, Medical Isotope and Cyclotron Facility, Department of Oncology, Edmonton, AB, Canada
2 shared publications- Katherine Gagnon
GE Healthcare, GEMS PET Systems, Uppsala, Sweden
2 shared publications - Svetlana V. Selivanova
Center for Radiopharmaceutical Sciences, ETH Zurich, Zurich, Switzerland
2 shared publications
Latest Publications
- Open Access
- 2 January 2024
- Published by Springer Nature in EJNMMI Radiopharmacy and Chemistry
- Vol. 9 (1) , 1-29
Position paper to facilitate patient access to radiopharmaceuticals: considerations for a suitable pharmaceutical regulatory framework
Background: Nuclear medicine has made enormous progress in the past decades. However, there are still significant inequalities in patient access among different countries, which could be mitigated by improving access to and availability of radiopharmaceuticals. Main body: This paper summarises major considerations for a suitable pharmaceutical regulatory framework to facilitate patient access to radiopharmaceuticals. These include the distinct characteristics of radiopharmaceuticals which require dedicated regulations, considering the impact of the variable complexity of radiopharmaceutical preparation, personnel requirements, manufacturing practices and quality assurance, regulatory authority interfaces, communication and training, as well as marketing authorisation procedures to ensure availability of radiopharmaceuticals. Finally, domestic and regional supply to ensure patient access via alternative regulatory pathways, including in-house production of radiopharmaceuticals, is described, and an outlook on regulatory challenges faced by new developments, such as the use of alpha emitters, is provided. Conclusions: All these considerations are an outcome of a dedicated Technical Meeting organised by the IAEA in 2023 and represent the views and opinions of experts in the field, not those of any regulatory authorities.
- 2 January 2024
- Published by Springer Nature in EJNMMI Radiopharmacy and Chemistry
- Vol. 9 (1) , 1-29
Open AccessPosition paper to facilitate patient access to radiopharmaceuticals: considerations for a suitable pharmaceutical regulatory framework
Background: Nuclear medicine has made enormous progress in the past decades. However, there are still significant inequalities in patient access among different countries, which could be mitigated by improving access to and availability of radiopharmaceuticals. Main body: This paper summarises major considerations for a suitable pharmaceutical regulatory framework to facilitate patient access to radiopharmaceuticals. These include the distinct characteristics of radiopharmaceuticals which require dedicated regulations, considering the impact of the variable complexity of radiopharmaceutical preparation, personnel requirements, manufacturing practices and quality assurance, regulatory authority interfaces, communication and training, as well as marketing authorisation procedures to ensure availability of radiopharmaceuticals. Finally, domestic and regional supply to ensure patient access via alternative regulatory pathways, including in-house production of radiopharmaceuticals, is described, and an outlook on regulatory challenges faced by new developments, such as the use of alpha emitters, is provided. Conclusions: All these considerations are an outcome of a dedicated Technical Meeting organised by the IAEA in 2023 and represent the views and opinions of experts in the field, not those of any regulatory authorities.
- Open Access
- 17 November 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (11) , 1622
Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications
This article highlights recent developments of SPECT and PET diagnostic imaging surrogates for targeted alpha particle therapy (TAT) radiopharmaceuticals. It outlines the rationale for using imaging surrogates to improve diagnostic-scan accuracy and facilitate research, and the properties an imaging-surrogate candidate should possess. It evaluates the strengths and limitations of each potential imaging surrogate. Thirteen surrogates for TAT are explored: 133La, 132La, 134Ce/134La, and 226Ac for 225Ac TAT; 203Pb for 212Pb TAT; 131Ba for 223Ra and 224Ra TAT; 123I, 124I, 131I and 209At for 211At TAT; 134Ce/134La for 227Th TAT; and 155Tb and 152Tb for 149Tb TAT.
- 17 November 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (11) , 1622
Open AccessTheranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications
This article highlights recent developments of SPECT and PET diagnostic imaging surrogates for targeted alpha particle therapy (TAT) radiopharmaceuticals. It outlines the rationale for using imaging surrogates to improve diagnostic-scan accuracy and facilitate research, and the properties an imaging-surrogate candidate should possess. It evaluates the strengths and limitations of each potential imaging surrogate. Thirteen surrogates for TAT are explored: 133La, 132La, 134Ce/134La, and 226Ac for 225Ac TAT; 203Pb for 212Pb TAT; 131Ba for 223Ra and 224Ra TAT; 123I, 124I, 131I and 209At for 211At TAT; 134Ce/134La for 227Th TAT; and 155Tb and 152Tb for 149Tb TAT.
- Top Cited PapersOpen Access
- 31 December 2020
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (1) , 49
Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications
This review outlines the accomplishments and potential developments of targeted alpha (α) particle therapy (TAT). It discusses the therapeutic advantages of the short and highly ionizing path of α-particle emissions; the ability of TAT to complement and provide superior efficacy over existing forms of radiotherapy; the physical decay properties and radiochemistry of common α-emitters, including 225Ac, 213Bi, 224Ra, 212Pb, 227Th, 223Ra, 211At, and 149Tb; the production techniques and proper handling of α-emitters in a radiopharmacy; recent preclinical developments; ongoing and completed clinical trials; and an outlook on the future of TAT.
- 31 December 2020
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (1) , 49
Top Cited PapersOpen AccessTargeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications
This review outlines the accomplishments and potential developments of targeted alpha (α) particle therapy (TAT). It discusses the therapeutic advantages of the short and highly ionizing path of α-particle emissions; the ability of TAT to complement and provide superior efficacy over existing forms of radiotherapy; the physical decay properties and radiochemistry of common α-emitters, including 225Ac, 213Bi, 224Ra, 212Pb, 227Th, 223Ra, 211At, and 149Tb; the production techniques and proper handling of α-emitters in a radiopharmacy; recent preclinical developments; ongoing and completed clinical trials; and an outlook on the future of TAT.
- 1 May 2018
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 60, 63-70
Robust high-yield ~1 TBq production of cyclotron based sodium [99mTc]pertechnetate
- 1 May 2018
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 60, 63-70
Robust high-yield ~1 TBq production of cyclotron based sodium [99mTc]pertechnetate
- Open Access
- 20 July 2016
- Published by Wiley in Journal of Internal Medicine
- Vol. 280 (2) , 136-138
Amyloid: a multifaceted player in human health and disease
Content List – Read more articles from the symposium: Amyloid ‐ a multifaceted player in human health and disease.
- 20 July 2016
- Published by Wiley in Journal of Internal Medicine
- Vol. 280 (2) , 136-138
Open AccessAmyloid: a multifaceted player in human health and disease
Content List – Read more articles from the symposium: Amyloid ‐ a multifaceted player in human health and disease.
- 1 April 2016
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 110, 193-199
Separation of [ 99m Tc]pertechnetate and molybdate using polyethylene glycol coated C18 and C30 resins
- 1 April 2016
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 110, 193-199
Separation of [ 99m Tc]pertechnetate and molybdate using polyethylene glycol coated C18 and C30 resins